Stockhub

Apellis Pharmaceuticals, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

13 August 2022

11 August 2022

26 July 2022

  • curprev 18:2518:25, 26 July 2022‎ Chris talk contribs‎ 1,566 bytes +1,566‎ Created page with "Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) dise..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Apellis_Pharmaceuticals,_Inc.’